Find PSC research studies
The following information relates to UK trials in Primary Sclerosing Cholangitis. For worldwide information, see ClinicalTrials.gov. In the UK, you can check on the UK Clinical Trials Gateway for details of current research trials.
Taking part in a research trial is a big step, and you should find out as much as you can about the trial before making a decision to take part. We have shown contact details for each trial below and we recommend that you ask for the Patient Information Sheet for each trial you're interested in, to read and digest in your own time. It's perfectly acceptable (and encouraged!) to ask questions about anything you don't fully understand. There is no pressure to take part once you have the information so do remember to get back in touch with the researchers if you wish to go ahead and be considered for the trial.
***Please note that your own hospital team may be conducting their own PSC studies (not mentioned here), and that they can also help you enter the UK-PSC study***
NorUrsodeoxycholic Acid in the Treatment of PSC
EudraCT Number: 2016-003367-19
The aim of this study is to compare norursodeoxycholic acid (NorUrso, NorUDCA) with placebo in the treatment of primary sclerosing cholangitis.
- Dr Jane Collier, John Radcliffe Hospital, Oxford
- Dr. Simon Rushbrook, Norfolk and Norwich Hospitals, Norwich
- Dr Palak Trivedi, Queen Elizabeth Hospital, Birmingham
- Dr. Douglas Thorburn, Royal Free Hospital, London
- Dr. Michael Williams, Royal Infirmary, Edinburgh
- Dr. Mark Hudson, Freeman Hospital, Newcastle upon Tyne,
- Prof. Aiden McCormick/ Dr. Ross McNicholas, St. Vincent's University Hospital, Dublin
Selected mesenchymal stromal cells to reduce liver inflammation
ISRCTN Identifier: ISRCTN73586959
The aim of this study is to investigate whether patients with primary sclerosing cholangitis (PSC) or autoimmune hepatitis (AIH) can be safely and effectively treated with a therapy called mesenchymal stromal cells (MSC).
Miss Rebecca Storey email@example.com
Call 0121 371 8118
Paternally Inherited Phenotypes in Cholestasis Study - (PIP-C)
ClinicalTrials.gov Identifier: NCT03337074
This study is investigating whether cholestatic liver diseases such as PSC can impact the structure and function of sperm. This is important because changes to the sperm can affect the health of the children conceived from those sperm. In this study, the health of 16 – 25 year-old children of fathers with cholestatic liver diseases such as PSC is also being investigated.
The study has 2 arms, the Sperm Epigenome arm and the Outcomes arm. Each participant can decide if they are eligible/would like to take part in one or in both arms of the study.
- In the Sperm Epigenome arm, the structure and function of sperm from men with PSC and other cholestatic liver disorders will be investigated and compared to the structure and function of sperm from healthy men.
- In the Outcomes arm, basic health parameters in fathers who had PSC or another cholestatic liver disease either before or after their child was conceived will be investigated, as well as basic health parameters in their child when they are aged between 16 and 25 years old.
UK locations: King's College Hospital, London Guy's Hospital NHS Foundation Trust, London
The PSC FNA Liver Study
The study is open to people who are 18 years or over in the UK with PSC able to make 1-2 visits to the John Radcliffe Hospital, Oxford.
Researchers from the University of Oxford are looking for people to take part in a study looking at the differences between immune cells in the livers of people with primary sclerosing cholangitis (PSC) and those with other liver diseases.
This will further our understanding of the processes involved in and the causes of PSC, and outcomes may potentially identify new beneficial therapies.
If you think you might be interested in taking part or if you would like to discuss the study further, please contact Dr Kate Williamson, the chief investigator, who is based at the University of Oxford/John Radcliffe Hospital.
Click here for more information (PSC Patient Information Sheet)
UK Location: Oxford
Contact: Dr Kate Williamson
Update: 04 January 2018 PSC Support is funding an extension to the investigations in this study: read more
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis (BUTEO)
ClinicalTrials.gov Identifier: NCT02239211
This is a phase II study to determine the safety and preliminary efficacy of a human monoclonal antibody (BTT1023) which targets the vascular adhesion protein (VAP-1) and its use in the treatment of patients with primary sclerosing cholangitis (PSC).
Updated 25 September 2018